Azure OpenAI Gating Team for HIPAA / Modified Abuse Monitoring Appeal

Hello @Xavier Serrano

Thank you for providing the detailed background, as well as your Application ID 3636178.

I understand the urgency of your situation, especially given your clinical research timeline and the compliance requirements your organization must meet.

From your description, I understand that:

• You already have an executed HIPAA Business Associate Agreement (BAA) with Microsoft.

Your Statistical Analysis Plan requires both Zero Data Retention (ZDR) and No Human Review.

Your application for Modified Abuse Monitoring (MAM) was declined because your organization is not currently designated as a Managed Customer or working directly with a Microsoft account team.

As a result, you are unable to use the default Azure OpenAI configuration for your production workload.

Based on the current Azure OpenAI guidance, the path you're requesting is handled through the Azure OpenAI Gating and Trust & Safety review process, rather than through the standard Azure Support escalation process.

At this time, Microsoft Support does not have the ability to manually approve, override, or expedite Azure OpenAI gating decisions or Modified Abuse Monitoring requests. The published guidance states that the Azure Support team is not involved in the approval process and therefore cannot expedite or manually escalate these requests. Eligibility for Modified Abuse Monitoring is determined solely by the Azure OpenAI Gating and Trust & Safety teams based on Microsoft's current qualification criteria.

Although having an executed HIPAA BAA is an important prerequisite for processing Protected Health Information (PHI) with Azure OpenAI, it does not automatically qualify a customer for Modified Abuse Monitoring, Zero Data Retention, or No Human Review. These are separate programs with independent eligibility requirements.

For inquiries regarding your application or if you believe there is additional business or regulatory information that should be considered, the documented point of contact is:

csgate@microsoft.com

You may reply to the communication associated with Application ID 3636178 and include any additional supporting documentation, such as your clinical study protocols or regulatory requirements, to assist the Gating Team in their review.

Additionally, Microsoft recommends ensuring the following addresses are added to your organization's safe sender list to avoid missing any correspondence related to your application:

maccount@microsoft.com

csgate@microsoft.com

If your organization has access to a Microsoft Account Executive, Customer Success Account Manager (CSAM), FastTrack representative, or an eligible Microsoft Partner, they may also be able to engage the appropriate internal channels to discuss your scenario. However, the final determination for Modified Abuse Monitoring remains with the Azure OpenAI Gating and Trust & Safety teams.

Once a Modified Abuse Monitoring request has been approved, you can verify that the capability has been applied to your Azure OpenAI resource by reviewing the resource properties. The resource JSON should include the following capability:

{
  "name": "ContentLogging",
  "value": "false"
}

If this capability is not present or the value is not set to false, then abuse monitoring remains enabled for that Azure OpenAI resource.

At this time, there is no documented alternative path for Microsoft moderators or Azure Support engineers to manually route or override Gating Team decisions outside of the established application and review process. Any updates regarding your application will be communicated directly through the application process.

We understand that this may impact your project timeline and appreciate your patience while the appropriate team reviews your request.

Please refer this

Abuse Monitoring (Modified Abuse Monitoring overview): https://learn.microsoft.com/azure/ai-foundry/openai/concepts/abuse-monitoring

Questions about data privacy (includes 30-day storage + human review context): https://learn.microsoft.com/azure/ai-foundry/responsible-ai/openai/data-privacy

Request for Modified Abuse Monitoring form (aka.ms link referenced): https://aka.ms/oai/modifiedaccess

Azure OpenAI transparency note: https://learn.microsoft.com/legal/cognitive-services/openai/transparency-note

Limited access to Azure OpenAI (eligibility context): https://learn.microsoft.com/azure/ai-foundry/responsible-ai/openai/limited-access

I Hope this helps. Do let me know if you have any further queries.

If this answers your query, please do click Accept Answer and Yes for was this answer helpful.

Thank you!

Hello Xavier Serrano,

Greetings! Thanks for raising this question in the Q&A forum.

You have accurately described the situation, and I want to be direct with you about what is possible through this forum and what the correct escalation path is.

The Q&A forum is a community and moderator space and does not have a direct channel to the Azure OpenAI Gating or Trust and Safety teams. Moderators here cannot route your case or Application ID to those internal teams. The only supported path to reach them is through a formal Azure Support request, which I will explain below. That said, there are concrete steps you can take right now to escalate this effectively.

The core constraint you have already identified is accurate: Zero Data Retention is not a self-service setting in the Azure portal. It is a gated capability that requires Microsoft approval, and is only available to customers on an Enterprise Agreement (EA) or Microsoft Customer Agreement (MCA). Your current subscription type determines your eligibility, and the Gating team's decline of your application reflects this structural requirement rather than a judgment on your use case.

Here are the steps most likely to move your request forward given your deadline.

Raise an Azure Support request citing your clinical research use case explicitly. In the Azure portal, navigate to Help + support > New support request. Set the Issue type to Technical, select your Azure OpenAI resource, and describe your ZDR/Modified Abuse Monitoring requirement. Include your Application ID (3636178), the executed HIPAA BAA reference, your Statistical Analysis Plan's ZDR mandate, and the fact that your prior application was declined on managed customer grounds rather than on the merits of the use case. A Microsoft Support Engineer will coordinate with the Azure OpenAI product team and can flag your case for manual review even without a managed account designation in some circumstances. After submission, allow approximately 5 to 7 business days for the team to review and respond.

Pursue an Enterprise Agreement or Microsoft Customer Agreement to unlock formal eligibility. Both Modified Abuse Monitoring and ZDR require approval and are available to customers on an Enterprise Agreement or Microsoft Customer Agreement. They are not self-service portal settings. If your organisation does not already have an EA or MCA, contacting a Microsoft sales representative to establish one is the structural fix that removes the managed customer barrier entirely. Given your clinical research timeline, frame the urgency explicitly when engaging the sales team, as health-tech and research workloads are a recognised use case for expedited agreement processing.

Contact your Microsoft account team if one exists. If your organisation has any existing Microsoft relationship — through a CSP partner, an ISV programme, or a prior enterprise agreement of any kind — engage that contact directly and ask them to escalate your Modified Abuse Monitoring request internally. A Microsoft account team member can submit the request on your behalf, which is the standard intake path for managed customers.

In the interim, consider architectural mitigations to reduce PHI exposure. While your escalation is in progress, you can reduce risk by ensuring your GPT-4o prompts are de-identified before they reach the Azure OpenAI endpoint, with re-identification happening in your own infrastructure after the completion is returned. This does not satisfy a strict ZDR mandate but can serve as a documented interim control in a clinical research protocol. Additionally, confirm that your Azure OpenAI resource is deployed in a standard (non-Global, non-DataZone) deployment type in your required region to enforce data residency at the infrastructure level regardless of ZDR status.

Verify ZDR status once approved. When and if approval is granted, you can confirm it is active on your resource using the Azure CLI:

az cognitiveservices account show \
  -n <resourceName> -g <resourceGroup> \
  --query "properties.capabilities[?name=='ContentLogging'] | [0].value" \
  -o tsv

A result of false confirms that content logging and abuse monitoring storage have been disabled for that resource.

If this answer helps you kindly accept the answer which will help others who have similar questions.

Best Regards,

Jerald Felix.